Third Harmonic Bio, Inc. (THRD)
Largest Insider Buys in Sector
THRD Stock Price History Chart
THRD Stock Performance
About Third Harmonic Bio, Inc.
Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. …
Insider Activity of Third Harmonic Bio, Inc.
Over the last 12 months, insiders at Third Harmonic Bio, Inc. have bought $0 and sold $15.49M worth of Third Harmonic Bio, Inc. stock.
On average, over the past 5 years, insiders at Third Harmonic Bio, Inc. have bought $16.18M and sold $7.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 214,063 shares for transaction amount of $879,499 was made by BVF PARTNERS L P/IL (director) on 2022‑12‑20.
List of Insider Buy and Sell Transactions, Third Harmonic Bio, Inc.
| 2024-11-08 | Sale | Chief Medical Officer | 2,117 0.0055% | $15.00 | $31,755 | -19.00% | ||
| 2024-10-29 | Sale | See Explanation of Responses | 1M 2.4872% | $14.30 | $14.3M | -14.81% | ||
| 2024-10-28 | Sale | Chief Medical Officer | 2,673 0.007% | $15.00 | $40,095 | -14.28% | ||
| 2024-09-19 | Sale | CHIEF ADMINISTRATIVE OFFICER | 9,497 0.0236% | $14.29 | $135,685 | -13.37% | ||
| 2024-09-19 | Sale | Chief Medical Officer | 4,790 0.0125% | $15.00 | $71,850 | -13.37% | ||
| 2024-09-18 | Sale | CHIEF ADMINISTRATIVE OFFICER | 503 0.0012% | $14.00 | $7,042 | -4.96% | ||
| 2024-06-26 | Sale | CHIEF ADMINISTRATIVE OFFICER | 10,000 0.0217% | $12.46 | $124,569 | -0.88% | ||
| 2024-06-07 | Sale | Chief Development Oper Officer | 494 0.0012% | $14.17 | $7,000 | -12.32% | ||
| 2024-05-20 | Sale | Chief Development Oper Officer | 1,042 0.0025% | $14.00 | $14,588 | -12.92% | ||
| 2024-05-16 | Sale | Chief Development Oper Officer | 23,578 0.0576% | $14.04 | $331,066 | -11.88% | ||
| 2024-05-09 | Sale | CEO | 20,222 0.0428% | $12.18 | $246,300 | +1.99% | ||
| 2024-04-11 | Sale | CEO | 13,558 0.0287% | $12.19 | $165,214 | +3.88% | ||
| 2024-04-04 | Sale | CHIEF ADMINISTRATIVE OFFICER | 1,107 0.0019% | $10.00 | $11,070 | +22.97% | ||
| 2023-12-05 | Sale | Chief Administrative Officer | 12,863 0.023% | $10.30 | $132,484 | +26.25% | ||
| 2023-12-05 | Sale | Chief Medical Officer | 4,790 0.0084% | $10.03 | $48,062 | +26.25% | ||
| 2022-12-20 | director | 214,063 0.153% | $4.11 | $879,499 | +28.50% | |||
| 2022-09-19 | 10 percent owner | 300,000 0.887% | $17.00 | $5.1M | -70.12% | |||
| 2022-09-19 | 300,000 0.887% | $17.00 | $5.1M | -70.12% | ||||
| 2022-09-19 | 300,000 0.887% | $17.00 | $5.1M | -70.12% |
Insider Historical Profitability
| BVF PARTNERS L P/IL | See Explanation of Responses | 176692 0.3921% | $10.84 | 1 | 1 | +28.5% |
| Atlas Venture Fund XI, L.P. | 10 percent owner | 10313763 22.8898% | $10.84 | 1 | 0 | |
| ORBIMED ADVISORS LLC | 5779071 12.8257% | $10.84 | 1 | 0 | ||
| Bonita David P | 5779071 12.8257% | $10.84 | 1 | 0 |